THC and the 5-HT2A Receptor: What’s Going On?
THC binding to 5-HT2A may activate signaling pathways that cause negative effects on cognition and memory.
Depression - Page 4
Psychedelic-Assisted Therapy in the Post-Pandemic Era
In the wake of Covid-19, psychedelic-assisted therapy is gaining attention.
Cybin’s Sublingual Psilocybin Strips Head to Clinical Trials for Dose-Finding
The first trial will determine the sublingual dose equivalent to 25 mg psilocybin administered orally.
Examining the Cognitive Neuroscience of Psychedelics
The new REBUS model helps explain the subjective and neurochemical effects of psychedelics on the brain.
Psilocybin to Treat Anxiety and Depression in Cancer Patients
Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
Noribogaine is More Effective Than Fluoxetine in Reducing Depressive Symptoms in Rat Model
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
Antidepressant-Like Effect with A Single Dose of Ibogaine and Noribogaine in Rats
This is the first preclinical study to examine the anti-depressive effects of ibogaine and noribogaine.
Psilocybin Superior to Ketamine for Prolonged Antidepressant-Like Effects (Rodent Model)
Results support the idea that serotonin 5-HT2A receptor-directed therapeutic strategies may be superior to ketamine-based treatments for depression.
Emotional Adjustment: The Modulatory Influence of Psilocybin on the Amygdala
Recent research suggests that psilocybin causes changes in amygdala activity opposite to those seen in conventional antidepressant treatment.
Positive Effects of Single-Dose Psilocybin Last Nearly 5 Years
After 4.5 years, 60-80% of the study participants with life-threatening cancer still experienced significantly decreased anxiety or antidepressant effects.